-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Antiplate plate plate therapy increases the risk of hematoma expansion in patients with cerebral hemorrhage (ICH), and the effect on the patient's functional prognosis is not yet clear.
Recently, a research article was published in JAHA, an authoritative journal in the field of cardiovascular disease, which is an exploratory analysis of the trial of double-blind, randomized, placebo-controlled TICH-2 (treatment of cerebral hemorrhage patients with acetate, which analyzed the efficacy of treatment with methylacycline in patients with spontaneous ICH within 8 hours of onset).
researchers conducted multivariate logistic regression and sequential regression to explore the relationship between pre-ICH antiplatelet therapy and 24-hour hematoma enlargement and 90-day improved Rankin scale scores, as well as the effects of aminocyclic acid.
of the 2,325 patients, 611 (26.3%) received pre-ICH antiplateplate therapy.
were older than the non-antiplate plateplate group (average age was 75.7 vs. vs. 66.5 years), ischemic heart disease (25.4% vs. 2.7%), ischemic stroke (36.2% vs. 6.3%), indoor cerebral hemorrhage (40.2% vs. 27.5%) are more likely, baseline hematoma volume (28.1 vs. 22.6 mL) is greater.
significantly increased risk of pre-ICH plateroid therapy associated with hematoma enlargement (corrected ratio ratio of 1.28; 95% CI is 1.01-1.63), while improved Rankin Table scores indicate a shift to adverse outcomes (corrected OR is 1.58; 95% CI is 1.32-1.91) and a higher risk of death on the 90th day (corrected OR is 1.63; 95% CI is 1.25-2.11).
treatment reduced all ICH patients (corrected OR 0.76; 95% CI 0.62-0.93) and antiplatelet therapy subgroups (corrected OR is 0.. 61;95% CI is 0.41-0.91) Risk of hematoma enlargement, there is no significant interaction between pre-ICH antiplatelet and aminocyclic acid therapy (interaction P=0.248).
, antiplate plate plate treatment is independently associated with hematoma enlargement and adverse function prognosis.
whether or not antiplatelet drugs are used, acetate treatment can reduce hematoma enlargement.
